Skip to main content


EULAR 2023 – Day 3 Report

Jun 02, 2023

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article

EULAR 2023 – Day 2 Report

Jun 01, 2023

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial

Read Article
#EULAR2023 #OP0136 New Biomarkers in #lupus nephritis? Indoxyl sulfate and cytosine metabolite serum levels were associated with kidney damage but not SLEDAI and reduced following therapy with anifrolumab in Phase 2 RCT @RheumNow
An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts @rheumnow #EULAR2023 abst#OP0034
Prediction of RA early arthritis & clinically suspect arthralgia pts w/ AI analysis of MRIs scans: ✔️Feasible ✔️Accurate AUC 0.683 EA group AUC 0.727 CSA group ✔️Peformance = human experts ✚ Could identify new imaging biomarkers OP0002 #EULAR23 @Rheumnow

International Consensus on ANCA-Associated Vasculitis with Glomerulonephritis

May 22, 2023

Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease:

Read Article

Allergic Drug-Induced Arthritis (5.19.2023)

May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

  1. Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK

Read Article

Evidence-Based Guidelines for EGPA

May 16, 2023

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally,

Read Article
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

May 11, 2023

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Previous studies have shown an increased risk of VTE in DM patients, usually within 2 years of onset. Moreover, the FDA has recently

Read Article

National Population Insights (4.28.2023)

Apr 28, 2023

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article

Renal Function Safe With Pegloticase-MTX Combo for Gout

MedPage Today
Apr 18, 2023

For patients with uncontrolled gout, estimated glomerular filtration rate (eGFR) remained stable with combination pegloticase (Krystexxa) and methotrexate treatment, researchers reported.

Looking more closely at the 12-month findings from the MIRROR trialopens in a new tab or window 

Read Article

Clinical Profile of RA-associated Interstitial Lung Disease

Apr 11, 2023

A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.

A single-center cohort study of 148 RA-ILD and 410 RA-non ILD patients compared clinical features

Read Article

Antiphospholipid Antibodies With Incident Cardiovascular Events

Apr 06, 2023

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?  A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted future

Read Article

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

Apr 04, 2023

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year. 

BRIDGE-PMR was a 21 week randomised

Read Article

Alcohol Differences in Urate Level Elevation

Mar 30, 2023

Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.

A cross-sectional study of Japanese adults (over age 20 yrs) examined effects of

Read Article

Gout - Hot Topics in March 2023

Mar 29, 2023

A number of new reports this month shed new light on old issues in Gout.

Read Article

LAVLI - A New Autoinflammatory Disorder

Mar 28, 2023

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic

Read Article

Anti-mesangial autoantibodies in IgA nephropathy

Mar 23, 2023

IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. In advanced stages of the disease, the buildup of IgA in the glomeruli disrupts kidney functioning and, in

Read Article
Urinary biomarkers in lupus nephritis ⁦@RheumNow⁩ and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology! #RNL2023
PMR lab studies by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Majority of patients will have elevated inflammatory markers. Rapid clinical response to low dose of steroid.

2022 EULAR Recommendations for ANCA-associated Vasculitis

Mar 16, 2023

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV.  A

Read Article

A Pilot Trial of Anifrolumab in Discoid Lupus

Mar 15, 2023

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article

Long-Term Survival of Idiopathic Inflammatory Myopathies

Mar 09, 2023

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.

This was a retrospective single-centre analysis of IIM patients

Read Article

Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis

Mar 09, 2023

A multinational study of rheumatoid arthritis (RA) patients shows a variety of post-translationally modified anti-modified protein antibodies (AMPA). While AMPA differed in different ethnic populations, their levels correlated with total serum IgG.

Read Article